# A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

> **NCT05218902** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 290 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Acute

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05218902
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-25
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218902, "A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05218902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*